• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH 25.0% 0.5¢

ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ATH
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
2
22:28 79 14K
22:28 Last post  Scottsmyname Comments Created with Sketch.  79  Views Created with Sketch.  14K 
ATH 26/03/24 3 803
26/03/24 Last post  Scottsmyname Comments Created with Sketch.  3  Views Created with Sketch.  803 
ATH 25/03/24 2 720
TRENDING NEWS

Diversification and low trading fees: Is this the ‘secret sauce’ to saving your investment portfolio?

NEWS
28 Mar 2024
25/03/24 Last post  Stockman Comments Created with Sketch.  2  Views Created with Sketch.  720 
ATH
3 posters, enough info to be big news ???
25/03/24 0 535
25/03/24 Last post  pivalde Comments Created with Sketch.  0  Views Created with Sketch.  535 
ATH
Claassen in AAN
24/03/24 2 600
24/03/24 Last post  pivalde Comments Created with Sketch.  2  Views Created with Sketch.  600 
ATH
The ape study in AAN
24/03/24 3 718
24/03/24 Last post  pivalde Comments Created with Sketch.  3  Views Created with Sketch.  718 
ATH
Stamler's presentation in AAN
24/03/24 1 358
24/03/24 Last post  pivalde Comments Created with Sketch.  1  Views Created with Sketch.  358 
ATH
iron accumulation/ cognition
23/03/24 1 410
23/03/24 Last post  pivalde Comments Created with Sketch.  1  Views Created with Sketch.  410 

See All Discussions arrow Created with Sketch.

Timeline

Alterity Receives a $3.9 million R&D Tax Incentive Refund
26 Mar 13:15
 
Change in substantial holding
25 Mar 08:21
 
Notice of Extraordinary General Meeting/Proxy Form
14 Mar 09:08
 
Becoming a substantial holder
07 Mar 08:15
 
Change in substantial holding
06 Mar 08:18
 
Notice Under Section 708A
04 Mar 10:34
 
View More arrow Created with Sketch.
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
47 58163299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 57489001 48
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 28/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.